Recent News

Komen recognizes Charles Perou with the Brinker Award, its top scientific honor

Komen recognizes Charles Perou with the Brinker Award, its top scientific honor

Susan G. Komen announced UNC Lineberger researcher Charles M. Perou, PhD, as the recipient of this year's Brinker Award for Scientific Distinction in Basic Science for his contributions to the understanding of breast cancer as distinct molecular subtypes that have prognostic value using cutting-edge cancer genomics tools.

Komen recognizes Charles Perou with the Brinker Award, its top scientific honor - Read More…

UNC’s Purvis earns NIH Director’s New Innovator Award

UNC’s Purvis earns NIH Director’s New Innovator Award

With a focus on stem cells, Jeremy Purvis, PhD, wants to tap the power of computer modeling to develop regenerative medicine solutions to medical conditions.

UNC’s Purvis earns NIH Director’s New Innovator Award - Read More…

Roy Williams’ Fast Break Against Cancer raises more than $200,000 – and counting

Roy Williams’ Fast Break Against Cancer raises more than $200,000 – and counting

North Carolina men’s basketball coach Roy Williams’ much beloved event has now raised more than $2.2 million over the years for UNC Lineberger Comprehensive Cancer Center, and the total will continue to grow, thanks to an online auction that is running through Oct. 17.

Roy Williams’ Fast Break Against Cancer raises more than $200,000 – and counting - Read More…

High up-front costs could delay access to life-saving blood cancer drugs for Medicare patients

High up-front costs could delay access to life-saving blood cancer drugs for Medicare patients

In the study published in the Journal of Clinical Oncology, UNC Lineberger researchers report that nearly a third of a group of patients with chronic myeloid leukemia, and who have federally-funded Medicare health insurance, did not start treatment within six months of diagnosis with any of three targeted drugs that have led to dramatic improvements in survival for the disease.

High up-front costs could delay access to life-saving blood cancer drugs for Medicare patients - Read More…